A highlight of all our trial and research achievements this past month:
DYNAMIC-Rectal closes patient enrolment
The DYNAMIC-Rectal trial closed to patient enrolment last month. The trial’s Study Chair, Associate Professor Jeanne Tie, hopes this trial will demonstrate the usefulness of ctDNA blood tests in deciding which patient will or will not require chemotherapy after rectal cancer surgery.
“We are hoping this helps avoid over-treatment of patients with unnecessary chemotherapy and identify those patients at high risk of recurrence who actually need chemotherapy treatment,” says Associate Professor Tie.
If DYNAMIC-Rectal is successful, then there is greater potential for ctDNA analysis to one day become incorporated into patients’ standard of care.
Thank you to all the patients and trial sites involved. We look forward to seeing the results of the study as the team now move into follow-up stage.
MASTERPLAN protocol published
Congratulations to the MASTERPLAN pancreatic cancer trial team who have had their trial protocol published in BMC Cancer. Led by Dr Andrew Oar and Professor Andrew Kneebone, this open trial is investigates whether stereotactic body radiotherapy in addition to modern chemotherapy is superior to the current standard of chemotherapy alone in both the neoadjuvant and definitive setting.
INTEGRATE IIa closes global patient enrolment
The INTEGRATE IIa gastro-oesophageal cancer trial closed to global enrolment, after recruiting 250 international patients. Led by Professor Nick Pavlakis, this study follows the success of the Phase II INTEGRATE study, which demonstrated a positive signal with regorafenib. The purpose of INTEGRATE IIa is to determine whether Regorafenib improves overall survival as a third line therapy in refractory advanced gastro-oesophageal cancer. The trial will now move in to analysis phase. Well done to all involved.
NABNEC enrolment closing soon
The NABNEC NETs clinical trial will be closing to patient enrolment 31 December 2021. This trial is comparing carboplatin plus nab-paclitaxel versus carboplatin plus etoposide in improving disease response rates in NETs patients. If you have any patients who may be suitable for this trial, find out more.